# US 2023/0407418 A1 · Massively scalable viral testing and asymptomatic surveillance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407418 A1
- Document ID: US20230407418A1
- Status: Published application
- Kind: A1
- Application number: 18/248,121
- Filed: 2021-10-06
- Published: 2023-12-21
- Earliest claimed: 2020-10-07
- Assignees: CZ Biohub SF, LLC; The Board of Trustees of the Leland Stanford Junior University
- Applicants: CZ Biohub SF, LLC; The Board of Trustees of the Leland Stanford Junior University
- Inventors: Sandy L. Klemm; William J. Greenleaf
- Web page: https://patentgrep.com/patent/US20230407418A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein is a method of rapidly identifying a patient that is positive for infection with a single-stranded RNA or DNA virus using a massively scalable viral testing method.

## Claims

### Claim 1

A method of rapid identification of SARS-CoV-2 positive patient(s) within a group comprising a plurality of patients in need of evaluation for SARS-CoV-infection comprising:
(a) separately incubating RNA-containing samples obtained from each of the plurality of patient with three or more collinear oligonucleotides,
wherein at least one of the three or more collinear oligonucleotides comprises a patient-specific identifying barcode sequence,
wherein the three or more collinear oligonucleotides have sequences complementary to a SARS-CoV-2 RNA target sequence, under conditions in which, if an RNA-containing sample comprises SARS-CoV-2 genomic RNA, an oligonucleotide-SARS-CoV-2 RNA complex is produced comprising the three or more collinear oligonucleotides hybridized at adjacent positions in the SARS-CoV-2 RNA target sequence,
thereby producing a plurality of incubated patient samples each of which comprises an oligonucleotide with a different patient-specific identifying barcode sequence, and
(b) pooling the plurality of incubated patient samples to produce a pooled sample;
(c) purifying oligonucleotide-SARS-CoV-2 complexes, when present, from the pooled sample;
(d) ligating the three or more collinear oligonucleotides hybridized to SARS-CoV-2 RNA in the oligonucleotide-SARS-CoV-2 complexes, if present, to produce ligation products comprising patient-specific identifying barcode sequences, and
(e) amplifying the ligation products, if present, to produce amplicons,
(f) detecting the amplicons,
wherein detection of amplicons in a pooled sample indicates that one or more of the patient samples comprises SARS-CoV-2 RNA and one or more of the patients is positive for the presence of SARS-CoV-2.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
(g) performing an asymmetric RNaseH-dependent PCR on a positive pool to provide a library of nucleic acid molecules for sequencing, wherein the asymmetric PCR comprises amplification using patient-specific primers, each of which hybridizes to a patient-specific barcode sequence, and is present in approximately the same limiting concentration; and
(h) sequencing the library of nucleic acid molecules to determine the patient-specific identifier sequences, thereby identifying a SARS-CoV-2-positive patient.

### Claim 3 (depends on 1)

The method of claim 1 wherein the ligating in step (d) comprises combining the pooled sample with a DNA ligase that comprises RNA-splinted DNA ligase activity.

### Claim 4 (depends on 3)

The method of claim 3, wherein the DNA ligase is Chlorella virus DNA ligase PBCV-1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 RNA target sequence is in a region of the SARS-CoV-2 genome that has low secondary structure and each of the collinear oligonucleotides has a GC content from about 45% to about 55%.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient-specific barcode sequence is at the 3′ end of the 5′-most collinear oligonucleotide; or is at the 5′ end 3′ of the 3′-most collinear oligonucleotide; or two of the three or more collinear oligonucleotides comprise patient-specific barcode sequences and the ligation products comprise two patient-specific barcode sequences.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the amplification reaction of (d) is quantitative PCR; and/or each of the three oligonucleotides has a Tm of 55° C. or higher; and/or the oligonucleotide that hybridizes to the most 5′ position comprises the patient-specific identifier sequence and further comprises a unique molecular identifier sequence at the 5′ end of the patient-specific identifier sequence.

### Claim at position 9

10-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein each of the three oligonucleotides comprises one or more locked nucleic acid monomers; and/or wherein the 3′-most oligonucleotide is linked at its 5′ end to a purification moiety, optionally wherein the purification moiety is biotin.

### Claim at position 11

13-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the oligonucleotide that hybridized to the most 5′ position comprises a region at the 5′ end that is not complementary to the target region of SARS-CoV-2 to which the oligonucleotide binds, but is reverse complementary to the first four nucleotides in the 3′ end that are complementary to the target region of the SARS-CoV-2 target region and form a stem-loop structure in the absence of viral template.

### Claim 16 (depends on 1)

The method of claim 1, wherein the oligonucleotide that hybridizes in the 5′ position comprises the patient-specific identifier sequence and at least said 5′ most oligonucleotide is present in at least 2-fold molar excess of the SARS-CoV-2 nucleic acid.

### Claim 17 (depends on 1)

The method of claim 1, further comprising a step of incubating the hybridized complex with a 5′ exonuclease after (a) and prior to (b).

### Claim 18 (depends on 1)

The method of claim 1, wherein the Tm of each of the three collinear oligonucleotides is above 80° C., or wherein the Tm of each of the three collinear oligonucleotides is in the range of 60° C. to 95° C.

### Claim 19

(canceled)

### Claim 20

A method of rapid identification of SARS-CoV-2 positive patient(s) within a group comprising a plurality of patients in need of evaluation for SARS-CoV-2 infection comprising:
(a) separately incubating RNA-containing samples obtained from each of the plurality of patients with an oligonucleotide comprising a patient-specific barcode, wherein the oligonucleotide comprises a sequence complementary to a SARS-CoV-2 target sequence, under conditions in which, if an RNA-containing sample comprise SARS-CoV-2 genomic RNA, an oligonucleotide-SARS-CoV-2 RNA complex is produced comprising the oligonucleotide hybridized to the SARS-CoV-2 RNA,
thereby producing a plurality of incubated patient samples each of which comprises an oligonucleotide with a different patient-specific identifying barcode sequence
(b) pooling the plurality of incubated patient samples to produce a pooled sample;
(c) purifying oligonucleotide-SARS-CoV-2 RNA complexes, when present, from the pooled sample;
(d) performing a reverse transcriptase reaction to extend the oligonucleotide hybridized to the SAR-Co-V-2 RNA in the oligonucleotide-SARS-CoV-2 RNA complexes; and
(e) amplifying the ligation products, if present, to produce amplicons; and
(f) detecting the amplicons,
wherein detection of amplicons in a pooled sample indicates that one or more of the patient samples comprises SARS-CoV-2 RNA and one or more of the patients is positive for the presence of SARS-CoV-2.

### Claim 21 (depends on 20)

The method of claim 20, further comprising
(g) performing an asymmetric RNaseH-dependent PCR on a positive pool to provide a library of nucleic acid molecules for sequencing, wherein the asymmetric PCR comprises amplification using patient-specific primers, each of which hybridizes to a patient-specific barcode sequence, and is present in approximately the same limiting concentration; and
(h) sequencing the library of nucleic acid molecules to determine the patient-specific identifier sequences, thereby identifying a SARS-CoV-2-positive patient.

### Claim 22 (depends on 20)

The method of claim 20, wherein the SARS-CoV-2 RNA target sequence is in a region of the SARS-CoV-2 genome that has low secondary structure and the oligonucleotide has a GC content from about 45% to about 55%.

### Claim 23 (depends on 20)

The method of claim 20, wherein the amplification reaction of (e) is quantitative PCR; and/or the oligonucleotide comprises one or more locked nucleic acid monomers; and/or the oligonucleotide is linked to a purification moiety, optionally biotin.

### Claim at position 21

24-26. (canceled)

### Claim 27 (depends on 20)

The method of claim 20, wherein the oligonucleotide comprises a region at the 5′ end that is not complementary to the target region of SARS-CoV-2 to which the oligonucleotide binds, but is reverse complementary to the first four nucleotides in the 3′ end that are complementary to the target region of the SARS-CoV-2 target region and form a stem-loop structure in the absence of viral template.

### Claim 28 (depends on 20)

The method of claim 20, wherein the oligonucleotide is present in at least 2-fold molar excess of the SARS-CoV-2 nucleic acid; and/or the method further comprises a step of incubating the hybridized complex with a 3′ exonuclease prior to (d); and/or the Tm of the oligonucleotide is above 80° C. or is in the range of 65° C. to 95° C.

### Claim at position 24

29-31. (canceled)

### Claim 32

A method of rapid identification of single-stranded RNA (ssRNA) virus-positive patient(s) within a group comprising a plurality of patients in need of evaluation for infection with a ssRNA virus, comprising:
(a) separately incubating RNA-containing samples obtained from each of the plurality of patient with three or more collinear oligonucleotides,
wherein at least one of the three or more collinear oligonucleotides comprises a patient-specific identifying barcode sequence,
wherein the three or more collinear oligonucleotides have sequences complementary to a ssRNA virus target sequence, under conditions in which, if an RNA-containing sample comprises ssRNA virus genomic RNA, an oligonucleotide-viral RNA complex is produced comprising the three or more collinear oligonucleotides hybridized at adjacent positions in the ssRNA virus RNA target sequence,
thereby producing a plurality of incubated patient samples each of which comprises an oligonucleotide with a different patient-specific identifying barcode sequence, and
(b) pooling the plurality of incubated patient samples to produce a pooled sample;
(c) purifying oligonucleotide-viral RNA complexes, when present, from the pooled sample;
(d) ligating the three or more collinear oligonucleotides hybridized to viral RNA in the oligonucleotide-viral RNA complexes, if present, to produce ligation products comprising patient-specific identifying barcode sequences, and
(e) amplifying the ligation products, if present, to produce amplicons,
(f) detecting the amplicons,
wherein detection of amplicons in a pooled sample indicates that one or more of the patient samples comprises ssRNA virus RNA and one or more of the patients is positive for infection with the ssRNA virus.

### Claim 33 (depends on 32)

The method of claim 32, further comprising:
(g) performing an asymmetric RNaseH-dependent PCR on a positive pool to provide a library of nucleic acid molecules for sequencing, wherein the asymmetric PCR comprises amplification using patient-specific primers, each of which hybridizes to a patient-specific barcode sequence, and is present in approximately the same limiting concentration; and
(h) sequencing the library of nucleic acid molecules to determine the patient-specific identifier sequences, thereby identifying a patient infected with the ssRNA virus.

### Claim 34 (depends on 32)

The method of claim 32, wherein the ligating in step (d) comprises combining the pooled sample with a DNA ligase that comprises RNA-splinted DNA ligase activity, optionally wherein the DNA ligase is Chlorella virus DNA ligase PBCV-1.

### Claim 35

(canceled)

### Claim 36 (depends on 32)

The method of claim 32, wherein the SARS-CoV-2 RNA target sequence is in a region of the SARS-CoV-2 genome that has low secondary structure and each of the collinear oligonucleotides has a GC content from about 45% to about 55%.

### Claim 37 (depends on 32)

The method of claim 32, wherein the patient-specific barcode sequence is at the 3′ end of the 5′-most collinear oligonucleotide; or the patient-specific barcode sequence at the 5′ end 3′ of the 3′-most collinear oligonucleotide; or the patient-specific barcode sequence at the 5′ end 3′ of the 3′-most collinear oligonucleotide.

### Claim at position 31

38-39. (canceled)

### Claim 40 (depends on 32)

The method of claim 32, wherein the amplification reaction of (e) is quantitative PCR.

### Claim 41 (depends on 32)

The method of claim 32, wherein each of the three oligonucleotides has a Tm of 55° C. or higher; and/or the oligonucleotide hybridizing to the most 5′ position comprises the patient-specific identifier sequence and further comprises a unique molecular identifier sequence at the 5′ end of the patient-specific identifier sequence.

### Claim 42

(canceled)

### Claim 43

A method of rapid identification of ssRNA virus-positive patient(s) within a group comprising a plurality of patients in need of evaluation for infection with a ssRNA virus, comprising:
(a) separately incubating RNA-containing samples obtained from each of the plurality of patients with an oligonucleotide comprising a patient-specific barcode, wherein the oligonucleotide comprises a sequence complementary to a ssRNA virus target sequence, under conditions in which, if an RNA-containing sample comprises ssRNA virus genomic RNA, an oligonucleotide-viral RNA complex is produced comprising the oligonucleotide hybridized to the viral RNA,
thereby producing a plurality of incubated patient samples each of which comprises an oligonucleotide with a different patient-specific identifying barcode sequence;
(b) pooling the plurality of incubated patient samples to produce a pooled sample;
(c) purifying oligonucleotide-viral RNA complexes, when present, from the pooled sample;
(d) performing a reverse transcriptase reaction to extend the oligonucleotide hybridized to the viral RNA in the oligonucleotide-viral RNA complexes; and
(e) amplifying the ligation products, if present, to produce amplicons; and
(f) detecting the amplicons,
wherein detection of amplicons in a pooled sample indicates that one or more of the patient samples comprises ssRNA virus RNA and one or more of the patients is positive for the presence of ssRNA virus.

### Claim 44 (depends on 43)

The method of claim 43, further comprising
(f) performing an asymmetric RNaseH-dependent PCR on a positive pool to provide a library of nucleic acid molecules for sequencing, wherein the asymmetric PCR comprises amplification using patient-specific primers, each of which hybridizes to a patient-specific barcode sequence, and is present in approximately the same limiting concentration; and
(g) sequencing the library of nucleic acid molecules to determine the patient-specific identifier sequences, thereby identifying a patient that is infected with the ssRNA virus.

### Claim 45 (depends on 43)

The method of claim 43, wherein the SARS-CoV-2 RNA target sequence is in a region of the SARS-CoV-2 genome that has low secondary structure and the oligonucleotide has a GC content from about 45% to about 55%; and or the amplification reaction of (e) is quantitative PCR; and/or the Tm of the oligonucleotide is in the range of 65° C. to 95° C.

### Claim at position 38

46-47. (canceled)
